- About
- Organization
- Organization Overview
- Dean’s Office
- Department of Bioengineering and Therapeutic Sciences
- Department of Clinical Pharmacy
- Department of Pharmaceutical Chemistry
- Quantitative Biosciences Institute
- Org Chart
- Research
- Education
- Patient Care
- People
- News
- Events
Kathryn Phillips, PhD
Professor

Phone: +1 415 502-8271
Fax: +1 415 502-0792
490 Illinois Street, Rm 32M
UCSF Box 0613
San Francisco, CA 94158
United States Links
Affiliations
Joint appointments
Education programs
UCSF centers, institutes, and research programs
What I do
My work focuses on the translation of new technologies into improved patient outcomes, particularly the translation of personalized/precision medicine—targeting health care interventions to patients based on their genetics—into clinical care and health policy.
Departmental research area
My research expertise
health services research, health economics, policy analysis, personalized medicine, precision medicine, access and use of new technologies - economic value and cost-effectiveness, translation of research into practice - particularly adoption and coverage/reimbursement, cancer screening, targeted cancer therapies, cross–disciplinary research, methodological approaches including secondary dataset analysis, systematic literature review, comparative effectiveness research, quantitative preference measurement (“stated choice” and “conjoint analysis”), women’s reproductive health
Clinical expertise
genetic testing, targeted therapies
Professional background
Degrees
PhD, Policy Analysis and Health Economics, University of California, Berkeley, 1991
MPA, Policy Analysis, Harvard Kennedy School, Harvard University, 1986
BA, Psychology, University of Texas at Austin, 1978
Postgraduate training
Post-Doctoral Fellowship, Prevention Sciences, University of California, San Francisco, 1993
Training and professional development
Diversity, Equity, and Inclusion Champion Training, University of California San Francisco, 2022
Biography
Kathryn A. Phillips, PhD, is Professor of Health Economics and Health Services Research in the Department of Clinical Pharmacy at UCSF. A leader in the application of new technologies to improve healthcare, she is the Founding Director of the UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS). She is a core faculty member in the UCSF Philip R. Lee Institute for Health Policy Studies and UCSF Helen Diller Family Comprehensive Cancer Center, and is affiliated with the Institute for Human Genetics, Department of Epidemiology and Biostatistics, Baker Computational Health Sciences Institute, and Global Health Sciences. She is the Founding Editor-in-Chief, Health Affairs Scholar: Emerging and Global Health Policy.
Kathryn focuses on the value of new technologies and how to most effectively and efficiently implement them into health care. Her core specialty is precision medicine — a new era of healthcare where medical interventions can be tailored to individual patients based on their unique genetic make-up. Her work spans multiple disciplines, including basic, clinical and social sciences, and brings together leading experts in academia, industry, healthcare, payers, and government. Her pioneering research on the application of health services research to personalized medicine has revealed insights on how to bridge the gap between emerging technologies and their use in the clinic. Kathryn led one of the earliest studies on the societal implications of pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001). Kathryn has also conducted seminal work on HIV, as her analysis of HIV home testing informed the FDA’s decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).
Kathryn has published ~200 peer-reviewed articles in major journals including JAMA, New England Journal of Medicine, Science, and Health Affairs and has been repeatedly named as being in the top 2% of authors for career-long citations in her field and in the top 100,000 of all researchers (Baas, 2021; Ioannidis 2020). She has had continuous funding from NIH as a Principal Investigator for 3 decades and was awarded a 5-year, $5M NIH grant to examine payer coverage and economic value for emerging genomic technologies. Kathryn serves on the editorial boards for Health Affairs and Value in Health and previously for JAMA Internal Medicine. She is a member of the National Academy of Medicine Roundtable on Genomics and Precision Health and served on a National Academy of Medicine consensus committee (2024-2025); and has served on the governing Board of Directors for GenomeCanada and as an advisor to the FDA, CDC, President’s Council of Advisors on Science and Technology, and the White House Office of Science and Technology. She has also served as an advisor to many diagnostics, sequencing, and pharmaceutical companies as well as venture capitalists. Kathryn is Chair of the Global Economics and Evaluation of Clinical Sequencing Working Group, and a member of one of the three evidence review committees for the Institute for Clinical and Economic Review (ICER). Her work has been quoted by the Washington Post, Wall Street Journal, New York Times, CNBC, Reuters, Newsweek, and other major news outlets.
Disclosures: Current
ICER: Dr. Phillips receives honoraria from the California Technology Assessment Forum (CTAF), which is an independent appraisal committee for the Institute for Clinical and Economic Review (ICER).
Illumina, Inc.: Dr. Phillips receives consulting from Illumina for support of the Global Economics and Evaluation of Clinical Genomics Sequencing Working Group (https://www.geecsecon.org/).
Disclosures: Completed in past 3 years
Precision Health Research, Singapore (PRECISE). Dr. Phillips is a member of the Health Economist Expert Network for PRECISE. PRECISE is a central entity set up to coordinate the government effort to implement Phase II of Singapore's 10-year National Precision Medicine strategy. (ended 2022)
Philips Healthcare. Dr Phillips was a member of a one-time meeting of the North American Oncology Advisory Community. Philips Healthcare provides healthcare solutions for diagnostic, treatment, and preventive care. (ended 2021)
Avia Health. Dr. Phillips was a consultant to Avia Health, which focuses on digital transformation to improve patient outcomes, streamline processes, and reduce costs. (ended 2022)
Association of Community Cancer Centers. Dr. Phillips served on the ACCC policy advisory board (ended 2021)
DeciBio Consulting. Dr Phillips served on a one-time advisory board on mult-cancer early detection tests (2021)
Roche Diagnostics. Dr. Phillips provided a one-time review of a clinical genomic profiling evidence assessment tool (2021)
Research keywords
- creating a high value health care system
- systematic literature review
- cancer
- health economics
- policy analysis
- Economic evaluation
- big data
- personalized/precision medicine
- cost-effectiveness analysis
- coverage/reimbursement policies
- secondary dataset analysis
- Insurer coverage
- utilization and cost-effectiveness of care
- population screening
- Health Services Research
- comparative effectiveness research
- value of diagnostics
- Technology Assessment, Biomedical
- genomics
- Cost-Benefit Analysis
- Insurance Carriers
- Health Expenditures
- Medicare
- Circulating Tumor DNA
- precision medicine
- Neoplasms
- Insurance Coverage
- health policy
- Insurance, Health, Reimbursement
- High-Throughput Nucleotide Sequencing
- Genetic Testing
- Exome
1. | Standing Member of National Academy of Medicine Roundtable on Genomics and Precision Medicine, National Academy of Medicine, 2021 |
2. | Named in top 2% of authors for career-long citations in field and in top 100,000 of all researchers, Ioannidis et al, PlosBiology 2020; Baas et al,Mendeley Data 2021, 2020-2021 |
3. | Dean's Awards For Outstanding Teaching (multiple), UCSF, 2019-2021 |
4. | Honorary Lectureship, University of British Columbia, 2018 |
5. | Honorary Lectureship, U of Maryland, 2017 |
6. | Rockefeller Foundation Residency, Bellagio Center Italy, 2016 |
7. | Most cited article award, Research Triangle Institute, 2010 |
8. | 50 Most Cited HIV Behavioral Researchers in Past Decade, Univ of CT, 2003 |
9. | Article in New England Journal of Medicine contributed to FDA decision to approve home HIV test, 1996 |
10. | UC Berkeley Graduate Fellowship, UC Berkeley, 1987-1988 |
Publications
Smith HS, Buchanan J, Goranitis I, IJzerman MJ, Lavelle TA, Marshall DA, Regier DA, Ungar WJ, Weymann D, Wordsworth S, Phillips KA, Jansen JP. Distributional cost-effectiveness analysis in genomic medicine: Considerations for addressing health equity. Value Health. 2025 May 06. |
Deverka PA, Arias JJ, Lin GA, Zwerling J, Phillips KA. Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations. J Alzheimers Dis. 2025 May; 105(2):433-442. |
Mrig EH, Phillips KA, Schlesinger M. Financial assistance programs for genetic testing: Effective, ethical, and sustainable pathways to improving access disparities? Genet Med. 2025 Mar 18; 27(6):101417. |
Trosman JR, Weldon CB, Kurian AW, Mrig E, Phillips KA. Implementation of Cancer Genomics in the United States: Views of Payers and Other Stakeholders on Challenges and the Role of Payers in Solutions. JCO Precis Oncol. 2025 Feb; 9:e2400822. |
Smith HS, Regier DA, Goranitis I, Bourke M, IJzerman MJ, Degeling K, Montgomery T, Phillips KA, Wordsworth S, Buchanan J, Marshall DA. Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework. Appl Health Econ Health Policy. 2025 Jan 20. |
Lin GA, Phillips KA, Fendrick AM. Corrigendum to "Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests" [Healthcare 11 (2023) 100705]. Healthc (Amst). 2024 Dec 11; 100755. |
Deverka PA, Lin GA, Phillips KA. Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests. JAMA. 2024 Dec 10; 332(22):1877-1878. |
Phillips KA. Open Access Publication at a Crossroads-Implications for Researchers and Beyond. JAMA Health Forum. 2024 Oct 04; 5(10):e242914. |
Lin GA, Coffman JM, Phillips KA. State Biomarker Testing Insurance Coverage Laws-Reply. JAMA. 2024 Sep 12. |
Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis. Mol Diagn Ther. 2024 09; 28(5):525-536. |
Lin GA, Coffman JM, Phillips KA. The State of State Biomarker Testing Insurance Coverage Laws. JAMA. 2024 06 11; 331(22):1885-1886. |
Marshall DA, Hua N, Buchanan J, Christensen KD, Frederix GWJ, Goranitis I, Ijzerman M, Jansen JP, Lavelle TA, Regier DA, Smith HS, Ungar WJ, Weymann D, Wordsworth S, Phillips KA. Paving the path for implementation of clinical genomic sequencing globally: Are we ready? Health Aff Sch. 2024 May; 2(5):qxae053. |
Phillips KA. Six months, strong impact. Health Aff Sch. 2024 Jan; 2(1):qxad087. |
Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis. medRxiv. 2023 Oct 28. |
Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis. Value Health. 2023 12; 26(12):1697-1710. |
Lin GA, Phillips KA, Fendrick AM. Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests. Healthc (Amst). 2023 09; 11(3):100705. |
Trosman JR, Weldon CB, Kurian AW, Pasquinelli MM, Kircher SM, Martin N, Douglas MP, Phillips KA. Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. Health Aff Sch. 2023 Jul; 1(1):qxad005. |
Phillips KA, Marshall DA, Adler L, Figueroa J, Haeder SF, Hamad R, Hernandez I, Moucheraud C, Nikpay S. Ten health policy challenges for the next 10 years. Health Aff Sch. 2023 Jul; 1(1):qxad010. |
Douglas MP, Ragavan MV, Chen C, Kumar A, Gray SW, Blakely CM, Phillips KA. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. J Natl Compr Canc Netw. 2023 06; 21(6):609-616.e4. |
Phillips KA. CMS Coverage With Evidence Development-Challenges and Opportunities for Improvement. JAMA Health Forum. 2022 09 02; 3(9):e223061. |
Weldon CB, Trosman JR, Liang SY, Douglas MP, Scheuner MT, Kurian A, Schaa KL, Roscow B, Erwin D, Phillips KA. Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes. J Genet Couns. 2022 12; 31(6):1394-1403. |
Deverka PA, Douglas MP, Phillips KA. Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. Health Aff (Millwood). 2022 03; 41(3):383-389. |
Arias JJ, Lin GA, Tyler AM, Douglas MP, Phillips KA. Geriatricians' Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer's Disease: A Qualitative Study. J Alzheimers Dis. 2022; 90(3):1011-1019. |
Phillips KA, Trosman JR, Douglas MP, Gelb BD, Ferket BS, Hindorff LA, Slavotinek AM, Berg JS, Russell HV, Devine B, Greve V, Smith HS. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genet Med. 2022 01; 24(1):238-244. |
Douglas MP, Lin GA, Trosman JR, Phillips KA. Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. J Community Genet. 2022 Feb; 13(1):75-80. |
Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. J Genet Couns. 2022 02; 31(1):130-139. |
Arias JJ, Phillips KA, Karlawish J. Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. JAMA Health Forum. 2021 07 02; 2(7):e211428. |
Scheuner MT, Douglas MP, Sales P, Ackerman SL, Phillips KA. Laboratory business models and practices: implications for availability and access to germline genetic testing. Genet Med. 2021 09; 23(9):1681-1688. |
Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and funding of clinical genomic sequencing globally. BMJ Glob Health. 2021 02; 6(2). |
Arias JJ, Tyler AM, Douglas MP, Phillips KA. Private payer coverage policies for ApoE-e4 genetic testing. Genet Med. 2021 04; 23(4):614-620. |
Phillips KA, Douglas MP, Marshall DA. Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation. JAMA. 2020 11 24; 324(20):2029-2030. |
Douglas MP, Gray SW, Phillips KA. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. J Natl Compr Canc Netw. 2020 07; 18(7):866-872. |
Phillips KA. Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy. Value Health. 2020 05; 23(5):527-528. |
Marshall DA, Grazziotin LR, Regier DA, Wordsworth S, Buchanan J, Phillips K, Ijzerman M. Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value Health. 2020 05; 23(5):566-573. |
Deverka PA, Douglas MP, Phillips KA. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. Value Health. 2020 05; 23(5):540-550. |
Mackay ZP, Dukhovny D, Phillips KA, Beggs AH, Green RC, Parad RB, Christensen KD, BabySeq Project Team. Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing. Value Health. 2020 05; 23(5):559-565. |
Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value Health. 2020 05; 23(5):551-558. |
Phillips KA, Marshall DA, Kurian AW. Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits? Per Med. 2019 09; 16(5):365-367. |
Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med. 2020 02; 22(2):283-291. |
Phillips KA, Trosman JR, Douglas MP. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA. 2019 06 25; 321(24):2403-2404. |
Zakinova A, Long-Boyle JR, French D, Croci R, Wilson L, Phillips KA, Kroetz DL, Shin J, Tamraz B. A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service. J Am Coll Clin Pharm. 2019 Jun; 2(3):214-221. |
Phillips KA, Douglas MP. The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. J Precis Med. 2018 Oct; 4. |
Phillips KA. Assessing the Value of Next-Generation Sequencing Technologies: An Introduction. Value Health. 2018 09; 21(9):1031-1032. |
Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value Health. 2018 09; 21(9):1054-1061. |
Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions. Value Health. 2018 09; 21(9):1033-1042. |
Trosman JR, Weldon CB, Gradishar WJ, Benson AB, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018 09; 21(9):1062-1068. |
Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genet Med. 2019 01; 21(1):152-160. |
Phillips KA. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018 06 19; 319(23):2379-2380. |
Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood). 2018 05; 37(5):710-716. |
Ginsburg GS, Phillips KA. Precision Medicine: From Science To Value. Health Aff (Millwood). 2018 05; 37(5):694-701. |
Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science. 2018 Apr 20; 360(6386):278-279. |
Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D, MedSeq Project. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 12; 20(12):1544-1553. |
Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2018 01; 20(1):165. |
Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips KA. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. Int J Technol Assess Health Care. 2017 Jan; 33(4):534-540. |
Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 07 12; 35(7):614-617. |
Marshall DA, MacDonald KV, Robinson JO, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. The price of whole-genome sequencing may be decreasing, but who will be sequenced? Per Med. 2017 May; 14(3):203-211. |
Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017 10; 19(10):1081-1091. |
Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228. |
Phillips KA, Douglas MP, Trosman JR, Marshall DA. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017 01; 20(1):47-53. |
Phillips KA. Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction. Value Health. 2017 01; 20(1):30-31. |
Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017 01; 20(1):40-46. |
Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips KA. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017 05; 19(5):559-567. |
Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016 12; 18(12):1295-1302. |
Phillips KA, Schleifer D, Hagelskamp C. Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Health Aff (Millwood). 2016 Apr; 35(4):647-53. |
Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep; 33(9):900-2. |
Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016 Feb; 18(2):111-6. |
Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015 Apr; 17(4):314-5. |
Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw. 2015 Mar; 13(3):311-8. |
Foster DG, Biggs MA, Phillips KA, Grindlay K, Grossman D. Potential public sector cost-savings from over-the-counter access to oral contraceptives. Contraception. 2015 May; 91(5):373-9. |
Knight SJ, Mohamed AF, Marshall DA, Ladabaum U, Phillips KA, Walsh JM. Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Med Decis Making. 2015 08 01; 35(6):734-744. |
Garfeld S, Douglas MP, MacDonald KV, Marshall DA, Phillips KA. Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Per Med. 2015 Jan 01; 12(1):13-22. |
Phillips KA, Pletcher MJ, Ladabaum U. Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing. Technol Health Care. 2015; 23(3):373-9. |
Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53. |
Balakrishnan N, Pritchard J, Ericson M, Grindem C, Phillips K, Jennings S, Mathews K, Tran H, Birkenheuer AJ, Breitschwerdt EB. Prostatitis, steatitis, and diarrhea in a dog following presumptive flea-borne transmission of Bartonella henselae. J Clin Microbiol. 2014 Sep; 52(9):3447-52. |
Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014 Mar; 16(3):251-7. |
Phillips KA, Sakowski JA, Liang SY, Ponce NA. Economic Perspectives on Personalized Health Care and Prevention. Forum Health Econ Policy. 2013 Sep 01; 16(2):S23-S52. |
Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U. Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract. 2012 May; 8(3 Suppl):e24s-30s. |
Beattie MS, Wang G, Phillips KA. Differences in US healthcare coverage policies in BRCA testing and potential implications. Per Med. 2012 Jan; 9(1):5-8. |
Wang G, Beattie MS, Ponce NA, Phillips KA. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med. 2011 Dec; 13(12):1045-50. |
Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips KA. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011 Oct; 13(10):853-60. |
Liang SY, Phillips KA, Wang G, Keohane C, Armstrong J, Morris WM, Haas JS. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care. 2011 Jun; 49(6):e1-8. |
Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011 May; 7(3 Suppl):e1s-7s. |
Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract. 2011 May; 7(3 Suppl):18s-24s. |
Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers's coverage of personalized medicine. Am J Manag Care. 2011 May; 17 Suppl 5 Developing:SP53-60. |
Johnson FR, Mohamed AF, Ozdemir S, Marshall DA, Phillips KA. How does cost matter in health-care discrete-choice experiments? Health Econ. 2011 Mar; 20(3):323-30. |
Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):13-25. |
Trosman JR, Van Bebber SL, Phillips KA. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract. 2010 Sep; 6(5):238-42. |
Van Bebber SL, Trosman JR, Liang SY, Wang G, Marshall DA, Knight S, Phillips KA. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per Med. 2010 Jul; 7(4):427-439. |
Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh JM, Marshall JK, Van Bebber S, Phillips KA. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ. 2009 Dec; 18(12):1420-39. |
Phillips KA, Marshall DA, Haas JS, Elkin EB, Liang SY, Hassett MJ, Ferrusi I, Brock JE, Van Bebber SL. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009 Nov 15; 115(22):5166-74. |
Ferrusi IL, Marshall DA, Kulin NA, Leighl NB, Phillips KA. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med. 2009 Mar; 6(2):193-215. |
Phillips KA, Liang SY, Van Bebber S, Canpers Research Group. Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Curr Opin Mol Ther. 2008 Jun; 10(3):260-6. |
Haas JS, Fitzmaurice G, Brawarsky P, Liang SY, Hiatt RA, Klabunde CN, Brown ML, Phillips KA. Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis. 2007 Oct; 4(4):A90. |
Issa AM, Phillips KA, Van Bebber S, Nidamarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, Bates DW. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007 Sep; 2(3):177-85. |
Marshall DA, Johnson FR, Phillips KA, Marshall JK, Thabane L, Kulin NA. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health. 2007 Sep-Oct; 10(5):415-30. |
Van Bebber SL, Liang SY, Phillips KA, Marshall D, Walsh J, Kulin N. Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Per Med. 2007 Aug; 4(3):341-350. |
Phillips KA, Liang SY, Ladabaum U, Haas J, Kerlikowske K, Lieberman D, Hiatt R, Nagamine M, Van Bebber SL. Trends in colonoscopy for colorectal cancer screening. Med Care. 2007 Feb; 45(2):160-7. |
Afable-Munsuz A, Gould H, Stewart F, Phillips KA, Van Bebber SL, Moore C. Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings. Contraception. 2007 Jan; 75(1):45-51. |
Phillips KA, Van Bebber SL, Issa AM. Initial development of an evidence base for personalized medicine's translation to clinical practice and health policy. Per Med. 2006 Nov; 3(4):411-414. |
Issa AM, Todd Weiss L, Tufail W, Phillips KA, Van Bebber SL. Innovation in personalized medicine: BiDil® as a case study for integrating clinical and policy developments. Per Med. 2006 Nov; 3(4):421-427. |
Van Bebber SL, Keegan HL, Phillips KA, Issa AM. Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study. Per Med. 2006 Nov; 3(4):415-419. |
Liang SY, Phillips KA, Nagamine M, Ladabaum U, Haas JS. Rates and predictors of colorectal cancer screening. Prev Chronic Dis. 2006 Oct; 3(4):A117. |
Keenan PS, Neumann PJ, Phillips KA. Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood). 2006 Sep-Oct; 25(5):1260-9. |
Phillips KA. The intersection of biotechnology and pharmacogenomics: health policy implications. Health Aff (Millwood). 2006 Sep-Oct; 25(5):1271-80. |
Phillips KA, Van Bebber S, Marshall D, Walsh J, Thabane L. A review of studies examining stated preferences for cancer screening. Prev Chronic Dis. 2006 Jul; 3(3):A75. |
Phillips KA, Van Bebber SL. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med Care Res Rev. 2006 Jun; 63(3):301-26. |
Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov. 2006 Jun; 5(6):463-9. |
Gellad WF, Huskamp HA, Phillips KA, Haas JS. How the new medicare drug benefit could affect vulnerable populations. Health Aff (Millwood). 2006 Jan-Feb; 25(1):248-55. |
Van Bebber SL, Phillips KA, Weitz TA, Gould H, Stewart F. Patient costs for medication abortion: results from a study of five clinical practices. Womens Health Issues. 2006 Jan-Feb; 16(1):4-13. |
Phillips KA, Ackerman MJ, Sakowski J, Berul CI. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm. 2005 Dec; 2(12):1294-300. |
Phillips KA, Liang SY, Haas JS, Stebbins M, Alldredge BK. Prescription drug dispensing limits and patterns. Manag Care Interface. 2005 Jul; 18(7):41-6. |
Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nat Rev Drug Discov. 2005 Jun; 4(6):500-9. |
Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004 Dec; 5(8):1139-49. |
Baker LC, Phillips KA, Haas JS, Liang SY, Sonneborn D. The effect of area HMO market share on cancer screening. Health Serv Res. 2004 Dec; 39(6 Pt 1):1751-72. |
Haggstrom DA, Phillips KA, Liang SY, Haas JS, Tye S, Kerlikowske K. Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes Control. 2004 Nov; 15(9):883-92. |
Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care. 2004 Jul; 10(7 Pt 1):425-32. |
Haas JS, Phillips KA, Sonneborn D, McCulloch CE, Baker LC, Kaplan CP, Pérez-Stable EJ, Liang SY. Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Med Care. 2004 Jul; 42(7):707-14. |
Phillips KA, Haas JS, Liang SY, Baker LC, Tye S, Kerlikowske K, Sakowski J, Spetz J. Are gatekeeper requirements associated with cancer screening utilization? Health Serv Res. 2004 Feb; 39(1):153-78. |
Liang SY, Phillips KA, Tye S, Haas JS, Sakowski J. Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services. Am J Manag Care. 2004 Feb; 10(2 Pt 1):99-107. |
Tye S, Phillips KA, Liang SY, Haas JS. Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography. Health Serv Res. 2004 Feb; 39(1):179-206. |
Phillips KA, Stotland NE, Liang SY, Spetz J, Haas JS, Oren E. Out-of-pocket expenditures for oral contraceptives and number of packs per purchase. J Am Med Womens Assoc (1972). 2004; 59(1):36-42. |
Haas JS, Lee LB, Kaplan CP, Sonneborn D, Phillips KA, Liang SY. The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health. 2003 Dec; 93(12):2105-10. |
Phillips KA. Important step forward in HIV-testing technologies [correction of technolgies]. Am J Prev Med. 2003 Aug; 25(2):167. |
Phillips KA, Veenstra D, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics. 2003 May; 4(3):231-9. |
Haas JS, Phillips KA, Baker LC, Sonneborn D, McCulloch CE. Is the prevalence of gatekeeping in a community associated with individual trust in medical care? Med Care. 2003 May; 41(5):660-8. |
Phillips KA, Chen JL. Willingness to use instant home HIV tests: data from the California Behavioral Risk Factor Surveillance Survey. Am J Prev Med. 2003 May; 24(4):340-8. |
Phillips KA, Bayer R, Chen JL. New Centers for Disease Control and Prevention's guidelines on HIV counseling and testing for the general population and pregnant women. J Acquir Immune Defic Syndr. 2003 Feb 01; 32(2):182-91. |
Phillips KA, Spetz J, Haas JS. Viagra and contraceptives. Health Aff (Millwood). 2003 Jan-Feb; 22(1):277. |
Phillips KA, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res. 2002 Dec; 37(6):1681-705. |
Phillips KA, Johnson FR, Maddala T. Measuring what people value: a comparison of "attitude" and "preference" surveys. Health Serv Res. 2002 Dec; 37(6):1659-79. |
Haas JS, Phillips KA, Sonneborn D, McCulloch CE, Liang SY. Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Med Care. 2002 Sep; 40(9):743-51. |
Oren E, McCart G, Phillips KA. Evaluating the potential impact of pharmacogenomics on ADRs. J Manag Care Pharm. 2002 Jul-Aug; 8(4):285-90. |
Phillips KA, Chen JL. Impact of the U.S. panel on cost-effectiveness in health and medicine. Am J Prev Med. 2002 Feb; 22(2):98-105. |